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Porcine Models of Muscular Dystrophy 
Abstract 
Duchenne muscular dystrophy is a progressive, fatal, X-linked disease caused by a failure to accumulate 
the cytoskeletal protein dystrophin. This disease has been studied using a variety of animal models 
including fish, mice, rats, and dogs. While these models have contributed substantially to our mechanistic 
understanding of the disease and disease progression, limitations inherent to each model have slowed 
the clinical advancement of therapies, which necessitates the development of novel large-animal models. 
Several porcine dystrophin-deficient models have been identified, although disease severity may be so 
severe as to limit their potential contributions to the field. We have recently identified and completed the 
initial characterization of a natural porcine model of dystrophin insufficiency. Muscles from these animals 
display characteristic focal necrosis concomitant with decreased abundance and localization of 
dystrophin-glycoprotein complex components. These pigs recapitulate many of the cardinal features of 
muscular dystrophy, have elevated serum creatine kinase activity, and preliminarily appear to display 
altered locomotion. They also suffer from sudden death preceded by EKG abnormalities. Pig 
dystrophinopathy models could allow refinement of dosing strategies in human-sized animals in 
preparation for clinical trials. From an animal handling perspective, these pigs can generally be treated 
normally, with the understanding that acute stress can lead to sudden death. In summary, the ability to 
create genetically modified pig models and the serendipitous discovery of genetic disease in the swine 
industry has resulted in the emergence of new animal tools to facilitate the critical objective of improving 
the quality and length of life for boys afflicted with such a devastating disease. 
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Abstract
Duchennemuscular dystrophy is a progressive, fatal, X-linked disease caused bya failure to accumulate the cytoskeletal protein
dystrophin. This disease has been studied using a variety of animal models including fish, mice, rats, and dogs. While these
models have contributed substantially to our mechanistic understanding of the disease and disease progression, limitations
inherent to eachmodel have slowed the clinical advancement of therapies, which necessitates the development of novel large-
animalmodels. Several porcine dystrophin-deficientmodels have been identified, althoughdisease severitymaybe so severe as
to limit their potential contributions to the field. We have recently identified and completed the initial characterization of a
natural porcine model of dystrophin insufficiency. Muscles from these animals display characteristic focal necrosis
concomitant with decreased abundance and localization of dystrophin-glycoprotein complex components. These pigs
recapitulate many of the cardinal features of muscular dystrophy, have elevated serum creatine kinase activity, and
preliminarily appear to display altered locomotion. They also suffer from sudden death preceded by EKG abnormalities. Pig
dystrophinopathymodels could allow refinement of dosing strategies in human-sized animals in preparation for clinical trials.
From an animal handling perspective, these pigs can generally be treated normally, with the understanding that acute stress
can lead to sudden death. In summary, the ability to create genetically modified pig models and the serendipitous discovery of
genetic disease in the swine industry has resulted in the emergence of new animal tools to facilitate the critical objective of
improving the quality and length of life for boys afflicted with such a devastating disease.
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Introduction
The dystrophin gene, found on the X chromosome, is among
the largest in the mammalian genome and is more than 2
megabases in length. When fully transcribed and translated, a
427 kDa full-length protein is produced from 79 exons, although
several smaller transcripts can also originate from the same
gene (Koenig et al. 1987; Muntoni et al. 2003). The dystrophin
protein is a functional link between the actin cytoskeleton and
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the dystrophin glycoprotein complex (DGC). Through the DGC,
dystrophin transmits force produced during muscle contraction
to large extracellular proteins and ultimately to tendons and
bones. The dystrophin protein contains four hinge regions and a
long rod domain composed of spectrin-like repeats (for review
Le Rumeur et al. 2010) and helps to protect the sarcolemma from
injury, particularly during eccentric contractions. In the case of
dystrophin deficiency, this functional connection is lost, as is
the capacity to transmit force via this mechanism along with
DGC component abundance and complex assembly. Dystrophin
deficiency results in a disease called Duchenne muscular dys-
trophy (DMD).
DMD is most commonly caused by deletions in the dystro-
phin gene, although point mutations and duplications also con-
tribute to the DMD population (Aartsma-Rus et al. 2006). In total,
approximately two thirds of cases are inherited, with the re-
mainder resulting from de novo mutations (Laing 1993). Boys
lacking the dystrophin protein product are afflicted with deteri-
orating muscles and a devastating prognosis that is typically
observed with locomotor deficits in early preschool years,
progressing toward death as a result of the failure of muscles
supporting cardiac and respiratory function. Becker muscular
dystrophy (BMD) is also caused by dystrophinmutations, result-
ing in either a failure to accumulate sufficient full-length dystro-
phin and/or the accumulation of a truncated dystrophin gene
product. Often this is the result of a deletion that maintains
the open reading frame. Disease severity is highly variable
in boys with BMD and ranges from nearly asymptomatic to
severity that closely parallels that seen in DMD (Beggs et al.
1991; Nicolas et al. 2015).
Whether through increased sarcolemmal Ca2+ permeability
(Liu et al. 2005; Lynch 2004; Moens et al. 1993; Morris et al. 2010;
Petrof et al. 1993; Selsby et al. 2010) or Ca2+ channel dysfunction
(Franco and Lansman 1990; Lansman and Franco-Obregon 2006;
Tutdibi et al. 1999), it is clear that dystrophicmuscle suffers a loss
of Ca2+ homeostasis. In terms of cellular function, loss of Ca2+
control leads directly to increased proteolysis. Indeed, both in-
creased activation of calpains and the proteasome system are
widely reported in dystrophic skeletal muscle (Selsby et al.
2010; Spencer andMellgren 2002). Further, mitochondria become
a secondary sink for Ca2+ storage leading to mitochondrial and
metabolic dysregulation (Basset et al. 2006; Vandebrouck et al.
2006). Superoxide production and free radical injury are
increased in dystrophic muscle (Selsby 2011; Tidball and
Wehling-Henricks 2007), likely due to increased calpain activity
and mitochondrial dysfunction. The combination of increased
cytosolic Ca2+, free radical production, and mitochondrial dys-
function and apoptotic signaling (Basset et al. 2006; Tews 2006)
in dystrophic muscle unfortunately culminates in myonuclear
loss and muscle fiber death. This cellular stress contributes to
an inflammatory response, further contributing tomuscle injury.
There is growing evidence that suppressed autophagy may also
be contributing to disease severity (De Palma et al. 2014; Hollinger
et al. 2013).
While there are numerous secondary pathologies contribut-
ing to disease severity, each represents a potential therapeutic
target. In addition, the goal of several novel treatment strategies
is to convert DMDpatients to BMDpatients and therebymitigate
disease severity. In one such approach, protein abundance of
utrophin, a dystrophin-related protein, is elevated. Numerous
reports have established that utrophin and dystrophin are
structurally similar (Blake et al. 1996), although not identical
(Li et al. 2010), such that utrophin can serve as an adequate sub-
stitute for dystrophin in the absence of dystrophin (Tinsley et al.
1998). In addition, utrophinmay play a role in satellite cell func-
tion, DGC localization, smoothmuscle function, and expression
of dystrophin splice variants, any one of which could potential-
ly affect muscle function and metabolism (Cohn et al. 2002;
Deconinck et al. 1997; Rafael et al. 2000). In another approach
called exon skipping, exons containing errors are artificially
spliced out, serving to reestablish the correct reading frame,
although it also results in the production of a truncated dystro-
phin protein product (Anthony et al. 2012; Mendell et al. 2013).
Lastly, gene therapy techniques attempt delivery of a miniatur-
ized utrophin or dystrophin gene to allow effective packaging
in adeno-associated viral particles. Termed micro-utrophins
(Odom et al. 2008) and micro-dystrophins (Shin et al. 2013),
these protein products have shown efficacy in animal models.
Hence, in addition to DMD, studies related to BMD are urgently
needed, as the BMD population seems likely to expand. A requi-
site requirement for the development of therapies for dys-





The mdx mouse is the research animal most commonly used to
study DMD. In the mdx mouse, dystrophic pathology is caused by
a point mutation in exon 23 leading to formation of a stop codon
and subsequently truncated protein (Bulfield et al. 1984). More re-
cently, mutagenesis techniques have generated at least four
novelmutations in themouse dystrophin gene that are designated
mdx2cv-5cv (Cox et al. 1993; Im et al. 1996). In addition to these
models, two mouse dystrophin knockout models have also
been developed (Kudoh et al. 2005; Wertz and Fuchtbauer
1998). The mdx mouse is an extremely well characterized
model of DMD and has been invaluable in the understanding
of disease pathogenesis and improving our mechanistic under-
standing of the disease. Further, it is widely used in the develop-
ment of new therapies.
However, for all of the many useful features of mdx mice,
there are a few significant drawbacks. For example, the disease
phenotype exhibited by mdx mice is much milder than that of
human DMD patients. These animals continue to be mobile, ex-
perience very little limb muscle fibrosis or adiposity, exhibit no
significant contractures, and have only a mildly reduced life
span (Banks and Chamberlain 2008; Chamberlain et al. 2007).
To date, several reasons explaining these observations have
been advanced, though little data supporting or refuting them
have been published. It could be that their small size and four-
legged means of locomotion spares muscles from continued
cycles of degeneration and regeneration (Wells and Wells 2005).
Alternatively, mice may have an inherently larger and/or faster
means of muscle regeneration than do humans (Wells and
Wells 2005). Further, inmdxmice, expression of utrophin is high-
er than in corresponding muscle from healthy mice and may be
better able to compensate for dystrophin deficiency in mice than
in humans (Lawet al. 1994). As thesewere recognized as potential
confounding variables, an mdx/utrophin−/− mouse line was de-
veloped, which has a far more severe phenotype (Deconinck
et al. 1997). Indeed, a number of additional mutations have
been superimposed on the mdx model in an effort to increase
disease severity (e.g., Sacco et al. 2010). While the disease pheno-
type is typically far more severe in thesemodels, they are no lon-
ger accurate genetic models of the human disease as these new
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knockouts often increase disease severity independent of the
dystrophin mutation.
Additionally, in many instances, there is a poor correlation
between effectiveness of therapies in mouse models to that
observed in human models (Duan 2011; Wells and Wells 2005).
Indeed, scaling up from a mouse to a dog or human presents a
number of challenges for conventional drug interventions as
well as gene and stem cell transfer-based approaches (discussed
below).
Golden Retriever Muscular Dystrophy (GRMD) Model
Identification and characterization of a larger dystrophin-defi-
cient animalmodel would contribute greatly to the advancement
of our understanding of the disease as well as our ability to treat
it. As a result, the GRMDmodel has been used extensively among
some research groups. In the GRMD model, the dystrophin gene
has a mutation in the 3′ end of intron 6 that results in the aber-
rant exclusion of exon 7 during splicing, and a frame shift,
which introduces a stop codon in exon 8 (Sharp et al. 1992).
This model features a phenotype that is similar in severity and
selectivemuscle injury to that seen in human patients (Kornegay
et al. 2003). Finally, these dogs are more similar in size to human
patients, helping to ease issues related to project scale-up (Duan
2011; Wells and Wells 2005).
Despite these positive aspects of the GRMDmodel, several de-
ficiencies warrant consideration of new large-animal models of
DMD. GRMD dogs have a high degree of variability, despite an
identical causative mutation (Cooper et al. 1988; Shimatsu et al.
2003). It is likely that at the root of this issue is variation in the
expression of alternatively spliced dystrophin gene products
and expression of resultant truncated translational products in
the muscles of GRMD dogs, leading to great phenotypic range
(Banks and Chamberlain 2008; Schatzberg et al. 1998). This may
be indicative of other underlying differences between the canine
and human diseases. While identification of mediators of this
differential expression is important and has great potential for
large therapeutic impacts, the high phenotypic variability
makes determining end points difficult and confounds data in-
terpretation (Bretag 2007). For example, despite being dystrophin
deficient, Ringo, a member of a Brazilian GRMD colony, behaves
normally (running, jumping, opening a door while on hind
limbs, and breeding) (Ambrosio et al. 2008). Furthermore, dystro-
phic dogs treated with corticosteroids exhibited a greater fre-
quency of calcified necrotic fibers and impairment of some
measures of muscle function (Liu et al. 2004). This is of great im-
portance because corticosteroids have been routinely used in the
care of human DMD patients since the 1970s and have consis-
tently improvedmuscle function. As corticosteroids are the stan-
dard of care, it is important to determine how novel drugs may
interact with corticosteroids in an animal model. Because corti-
costeroids exacerbate the disease in the GRMD model, it is not
the ideal large-animal model in which to make these compari-
sons. Despite the many favorable attributes of the dog model of
DMD, several deficiencies remain, necessitating the continued
search for alternative large-animal models of DMD.
Other Dystrophinopathy Models
The hypertrophic feline muscular dystrophy (HFMD) cat analog
of DMD was first diagnosed in a companion animal. Different
spontaneously occurring mutations can lead to HFMD, however
these mutations appear to be located at the muscle and Purkinje
promoter of the dystrophin gene (Gambino et al. 2014; Winand
et al. 1994). The feline model is rarely used as a research animal
because tongue and diaphragm hypertrophy lead to feeding dif-
ficulties, animal welfare concerns, and death (Carpenter et al.
1989; Gaschen et al. 1992).
Two independent labs have recently employed genome edit-
ing tools to induce dystrophin mutations in rats (Larcher et al.
2014; Nakamura et al. 2014). Nakamura and colleagues used
clustered, interspaced short palindromic repeats (CRISPR)/Cas
to induce deletions in exon 3 and/or exon 16 in inbred Wistar–
Imaichi rats. The rats showed muscle pathology consistent
withDMD; however, therewas large variation in severity between
individual animals (Nakamura et al. 2014). A stop codon in exon
23, as found in themdxmouse, was created in rats by Larcher and
colleagues utilizing transcription activator-like effector nucleas-
es (TALEN). The Dmdmdx rats have a phenotype similar to human
DMD patients including fatty infiltration and a cardiac defect. In
outbred Sprague-Dawley rats carrying this mutation, the pheno-
type is also consistent between animals. A benefit of ratmodels is
that rats are relatively easy to work with and have inexpensive
husbandry needs compared with large animals. However, issues
related to scale up, like in the mouse, would seem to limit the
usefulness of these models as translational tools.
Zebrafish dystrophinopathymodels are commonly used non-
mammalian models of DMD. Two strains are available: sapje,
with a nonsense mutation in exon 4, and sapje-like, with a dele-
tion of exon 62 leading to a stop codon in exon 63 (Bassett et al.
2003; Guyon et al. 2009). Since zebrafish embryos are translucent,
muscle damage can be visualized and quantified using polarized
light (Berger et al. 2012). The straightforward quantification
facilitates high throughput screening of disease-modifying
compounds (Kawahara et al. 2011; Waugh et al. 2014), testing
the efficacy of potential treatments (Berger et al. 2011; Li et al.
2014), and studies of disease pathology (Alexander et al. 2013;
Bassett et al. 2003). Even though zebrafish have proteins ortholo-
gous to those in the mammalian DGC (Chambers et al. 2001),
there are limitations to using zebrafish models including differ-
ences in taxonomy class, locomotion, and size.
Rationale for Porcine Models
of Dystrophinopathy
Despite the fact that DMD remains the most common fatal,
X-linked disease, development of therapeutic interventions is
moving at an alarmingly slow rate. Certainly, current animal
models have been essential in aiding our understanding of
DMDandhavemade contributions as preclinicalmodels. Howev-
er, their differences in body size, disease presentation, and
response to therapeutic interventions compared with humans
have hindered progress toward advances in patient care. With a
porcine model available, we anticipate that preclinical trials
would be far more representative and predictive of human out-
comes, because the pig genome is three times more similar to
that of the human than is the mouse (Wernersson et al. 2005)
and is much closer in anatomical size to humans than is the
mouse or dog.
As noted above, a significant hurdle is appropriately scaling
experimental medications from doses given to a mouse or dog
to those appropriate for a human patient. In many instances,
the dog is omitted from the translational pipeline, hence more
commonly the hurdle is scaling therapies from mouse to
human. In addition to differences in body size, there are also dif-
ferences in body composition, metabolic rate, and biological
chemistry that contribute to varied or underwhelming responses






/ilarjournal/article/56/1/116/661519 by guest on 27 January 2021
in humans despite strong preclinical data demonstrating efficacy
inmice. Failure to appropriately dose human subjects results in a
failure to accumulate sufficient drug-of-interest in the blood and/
or target tissues or to effect a desired modification of targeted
pathway activity. It may cause significant side effects leading to
failure of the clinical trial.
Similar to conventional intervention, scale up of gene therapy
approaches also faces significant challenges. Intramuscular gene
transfer and intravascular delivery of virus for whole-body trans-
fection have become routine in mouse models (Gregorevic et al.
2006, 2008; Zhang and Duan 2012). Unlike the mdx mouse, after
intramuscular viral delivery ofmicrodystrophin to DMD patients,
no transgene was detected (Mendell, Campbell, et al. 2010). This
may be due, in part, to an immune response to the transgene. The
viral vector itself can also provoke an immune response in pa-
tients (Mendell, Rodino-Klapac et al. 2010; Mingozzi et al. 2007),
which could interfere with transgene expression. Because of
the immune response encountered with intramuscular delivery,
there is concern that the higher titers required for systemic per-
fusion could trigger a stronger immune response, which would
be counter to the efficacy of the intervention and well-being of
the patient. Further, delivering virus directly to the entirety of
the musculature is logistically impractical. Large-animal models
can facilitate the optimization of approaches for systematic viral
delivery while at the same time evaluating the immunological
responses in multiple species.
Given these current problematic issues of scale-up, amodel of
human size would seem to be an invaluable tool. Minipigs (i.e.,
NIH minipig, Yucatan) can be managed to reach a size of
∼150 lbs at one year of age and ∼200 pounds at two years of age.
Domestic pigs used for agriculture can reach nearly 300 pounds
by six months of age and may exceed 500 pounds by one year of
age. An advantage of the larger size makes biopsies possible
such that longitudinal studies could be performed on the same
animal. Furthermore, logistics of scale-up, including dosages, ti-
ters, injection sites, dosing regimens, etc., could be better defined
prior to use in DMD patients. This has the cumulative benefit of
reducing the cost of clinical trials because (1) a very thorough pre-
clinical trial featuring pigs would be much cheaper than most
human clinical trials, (2) clinical trials could contain fewer groups
as dose determination and scale-up methods have already been
determined, and (3) interventions that would fail because of lim-
itations to scale-up or other toxicities discovered in moving to
large animals could be halted at the preclinical stage.
In addition to skeletal muscle dysfunction, dystrophinopathy
patients suffer a progressive cardiomyopathy. Indeed, respiratory
support therapies have been so successful in protecting respirato-
ry function that cardiomyopathy is growing in frequency as the
cause of death for DMDpatients (McNally 2007). Hence, it is imper-
ative that models of DMD have a cardiovascular system compara-
ble to the human cardiovascular system so that interventions will
be in the appropriate physiological context. In that regard, porcine
and human hearts are similar in terms of cardiac output, stroke
volume, mean arterial pressure, heart rate, and perfusion (Crick
et al. 1998; Thein and Hammer 2004). Moreover, the porcine
heart is so similar to the human heart that, in preparation for xe-
notransplantation, transgenic pigs designed to reduce rejection
have been developed (Ezzelarab et al. 2009; Lai et al. 2002; Weiss
et al. 2009), while pig xenographs are currently being used in hu-
mans for valve replacements as well as aortic root replacements
(Kon et al. 1999; LeMaire et al. 2009). Finally, amodel with a cardio-
myopathyprovides anopportunity to study themechanismof this




A tremendous amount of progress has been made in the last
decade with respect to genetically engineering pigs with specific
defects to recapitulate human disease phenotypes in a desirable
pig genetic background (Prather et al. 2013; Yang and Ross 2012).
The ability to make pigs carrying specific genetic modifications
has been accomplished through somatic cell nuclear transfer
(Rogers et al. 2008; Ross et al. 2012) and through the implementa-
tion of new gene-editing technologies such as TAL effector nucle-
ases (TALENs) (Prather et al. 2013) and the use of the CRISPR/Cas9
system (Whitworth et al. 2014).
We and others have pursued this genome modification
approach, resulting in the emergence of several new models of
dystrophinopathies in pigs. In 2013, Klymiuk and colleagues re-
ported a transgenic pig model with the exon corresponding to
human dystrophin exon 52 replaced with a neomycin selectable
marker cassette. The deletion of the exon resulted in a +1 frame
shift after the splicing of exon 51 to 53 (Klymiuk et al. 2013). The
model produces someof the cardinal features of DMD inhumans,
such as absence of dystrophin protein, a reduction in the abun-
dance and localization of DGC components, elevated serum cre-
atine kinase activity, and progressive fibrosis of muscle. The
model though is not without some significant drawbacks. At a
molecular level, themodel appears to express significantly great-
er utrophin than wild-type counterparts, a shortcoming of the
mdx mouse. Further, the severity of the disease in this pig
model is so great as to significantly limit its use as a research
tool as the majority of affected offspring died within the first
week of life. Hence, the opportunity to identify biomarkers
prior to an observable physical phenotype is greatly reduced, as
is the ability to introduce a therapeutic intervention early enough
in the course of the disease to curb disease progression and
severity over time.
Information regarding another porcine model of muscular
dystrophy is available only through the U.S. patent office (Exem-
plar Genetics Patent US 20140223589 A1). The patent claims that
these miniature pigs possess an exon 52 deletion and demon-
strate several characteristics consistent with DMD phenotypes
observed in boys with the disease, such as elevated serum crea-
tine kinase activity and lack of a functional dystrophin protein.
While several key features of this model still require further
characterization to determine its full potential, this model is
promising. Of potential concern is that the genetics of this
model appears to cause the same mutation (exon 52 deletion)
as the transgenic dystrophin knockout model above (Klymiuk
et al. 2013). Hence, there is the expectation that the severity of
the disease would be similar, although until the details of the
model are peer reviewed this is speculative.
We have also pursued the development of a miniature pig
model of muscular dystrophy. Our modification, accomplished
by the introduction of a neomycin selectable marker cassette
via homologous recombination, results in the in-frame deletion
of an exon in the rod domain of the dystrophin protein (Ross
et al., unpublished observations). We have recently begun pro-
ducing males carrying the modification. Anecdotally, they ap-
pear to develop fairly normally for the first two months of life.
Both phenotypic and molecular characterizations at multiple
time points in the first year are underway to determine the extent
to which this model recapitulates fundamental features of dys-
trophinopathies. Our expectation is that an in-frame dystrophin
mutation in the pig would result in amilder dystrophinopathy in
comparison with other existing transgenic pig models, such as
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the one developed by Klymiuk and colleagues (2013). An addi-
tional advantage of a miniature BMD-like model would be their
research importance in the event of successful deployment of
exon-skipping drugs, which would dramatically increase the
number of boys with a BMD-like phenotype.
While genetic modification of the pig genome offers the abil-
ity to create and utilize important animal models, the use of
transgenic pig models is hampered by federal regulations limit-
ing rapid, widespread use and distribution of the animals
(Maxmen 2012). Alternatively, the U.S. swine industry produces
over 100 million pigs per year. While the swine industry does
not actively pursue the identification of phenotypes for use as
biomedical models, some mutations have been identified, such
as pigs with malignant hyperthermia (MH) (Fujii et al. 1991),
severe combined immunodeficiency (SCID) (Ewen et al. 2014), and
our porcine BMD model (see below) (Hollinger et al. 2014;
Nonneman et al. 2012). These discoveries of spontaneously
occurring disease models are capable of making an impact on the
biomedical research community without the complications of
regulatory efforts associated with monitoring transgenic animals.
A Spontaneous Porcine Dystrophinopathy
Model
Discovery
A porcine stress syndrome symptomatically similar to ryanodine
receptor 1 (RYR1)-mediated porcine stress syndrome was discov-
ered in the U.S. Meat Animal Research Center’s swine research
population when two male siblings died of apparent stress after
transport at 12 weeks of age (Nonneman et al. 2012). Because the
population was free of the RYR1 mutation, it was initially thought
it could be an allelic form of porcine stress syndrome or MH. To
evaluate candidate genes associated with the stress syndrome,
the coding regions of porcine orthologs of human MH genes
RYR1, calcium channel, voltage-dependent, L type, alpha 1S sub-
unit (CACNA1S), carnitine palmitoyltransferase 2 (CPT2), and rya-
nodine receptor 2 (RYR2) were sequenced for SNP discovery and
mutationdetection in the proband’s family. Therewere no obvious
mutations identifiedwhennormal and affected siblingswere com-
pared, and the syndrome did not cosegregate with SNP alleles in
any of the human MH candidate genes. Matings were made with
the original sire, dam, and daughters to generate additional off-
spring to characterize the genetic basis of this syndrome. A pedi-
gree of 250 animals that included 49 affected pigs was genotyped
with the Illumina PorcineSNP60 beadchip (Ramos et al. 2009), and
a single region on the X chromosome (29–32 Mb) was associated
with the stress syndrome. The two most significant markers on
the beadchip (ALGA0099513 and ALGA0099514) are located in
intron 44 of the dystrophin gene (Nonneman et al. 2012).
Genetics
After discovering that the dystrophin gene was associated with
the stress syndrome, the exons and flanking intron boundaries
of DMD were sequenced from normal and affected pigs, and no
polymorphisms were identified near splice sites. Amplification
and sequencing of skeletalmuscle cDNA fromnormal and affect-
ed animals revealed no evidence of alternative splicing or dele-
tion of exons in the affected animals. Polymorphisms in the
promoter regions (P1, P2, and the muscle-specific promoter) did
not segregate with the disease. Six nonsynonymous polymor-
phisms were found in the coding region (Table 1), and only one
of these nonsynonymous changes, 85890_783, which causes the
amino acid change arginine to tryptophan at amino acid 1958
(R1958W) in exon 41, was significantly associated with the stress
syndrome. This SNP was as highly associated with the stress re-
sponse as the two most significant SNPs in intron 44 on the Illu-
mina PorcineSNP60 Beadchip. The C allele (arginine) was found
in all unaffected animals, and the Tallele (tryptophan)was hemi-
zygous in affected males and heterozygous in carrier females.
This change was predicted by PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/) to be damaging with a probability score of
0.983 (Nonneman et al. 2012).
To further characterize this variant, additional sequencing
of the locus in this population was performed. Because of the
size of the dystrophin gene, a DNA capture array (Agilent,
Santa Clara, CA) was designed for 2.33 Mb of pig genomic se-
quence spanning the DMD gene and included 146 kb upstream
of the first exon and 20 kb downstream of the last exon. The var-
iation between affected and normal pigs and two normal pools
of Duroc/Yorkshire and Landrace boars showed that affected
pigs shared a common haplotype that extended for about
750 kb. corresponding to a region ranging from intron 40 to in-
tron 59 of the dystrophin gene (DJ Nonneman, GA Rohrer, un-
published observations). This region includes the arginine to
tryptophan substitution in exon 41 and the twomost significant
Illumina Beadchip markers. This shared haplotype implies that
the mutation resides in this interval, and no other mutations
were found in this region. Thus the hypothesis that the Arg-
Trp mutation is responsible for the phenotype is strongly sup-
ported by the genetic evidence.
Phenotype
In affected pigs, dystrophin abundancewas decreased in allmus-
cles by ∼70% when assessed by Western blot; however, using an
immunohistochemical approach, the reduction in dystrophin
localization was noted in the diaphragm (70% reduction) and
the longissimus (90% reduction) but not the psoas (45% numeri-
cal reduction) (Hollinger et al. 2014; Nonneman et al. 2012).
Table 1. Nonsynonymous polymorphisms in pig DMD and their associations with the stress-induced phenotype
Marker Nucleotide Polymorphisma Amino Acid Location p-value
84000_82 1349 CRA R396G Exon 11 0.002
84002_411 1629 CAS H489Q Exon 12 0.0002
84339_200 2102 ARC N647S Exon 16 0.406
84339_333 2235 ACR T691T Exon 16 0.559
85890_783 6034 YGG R1958W Exon 41 1.06 × 10−23
ALGA0099513 Intron 44 2.19 × 10−23
ALGA0099514 Intron 44 2.19 × 10−23
85904_613 7274 CYG L2371P Exon 49 0.005
aPolymorphisms are shown by their IUB code within the codon.
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Likewise, α-sarcoglycan and dystroglycan abundance and locali-
zation followed a similar pattern in these muscles (Fortunato
et al. 2014; Hollinger et al. 2014). Litter size and sex distribution
of offspring were consistent with that found in a typical produc-
tion line, suggesting that dystrophin insufficiency does not affect
in utero survival. Further, growth of affected pigs and healthy lit-
termates was similar throughout the first 12months of life. Visu-
ally, pigs containing the polymorphism causing dystrophin
insufficiency appear similar to their unaffected littermates
throughout thefirst 12months of life. Consistentwith disease-re-
latedmuscle injury, serum creatine kinase activity is increased in
affected animals compared with healthy littermates. At two
months of age, a detailed histological study using several mus-
cles was conducted, which revealed focal necrotic lesions in
some, but not all, muscles selected for investigation (Hollinger
et al. 2014). For example, the diaphragm and longissimus con-
tained necrotic lesions; however, the psoas did not. It is unclear
if the muscle-specific response is due to frequency and type of
muscle use, where the diaphragm and longissimus are used reg-
ularly and the psoas is used sparingly. Alternatively, the fiber-
type distribution may also affect muscle injury because the
psoas is largely type I, which has been shown to be resistant to
dystrophic injury relative to other fiber types (Webster et al.
1988). Indeed, a novel therapeutic approach is to increase the fre-
quency of type I fibers within amuscle group as the complement
of proteins associated with the type I phenotype appears protec-
tive to dystrophic injury (Hollinger et al. 2013; Ljubicic et al. 2011;
Selsby et al. 2012). It is also unclear if the dystrophic psoas
contains less injury as a cause or an effect of the higher degree
of dystrophin and DGC localization.
Cardiomyopathy is another important consideration for ani-
malmodels of dystrophinopathies because it is quickly becoming
the leading cause of death for dystrophinopathy patients. In this
pig model, the myocardium appears free from lesions at two
months of age despite dystrophin insufficiency (JT Selsby,
JW Ross, DJ Nonneman, K Hollinger, unpublished observations).
At 12months of age, foci of necrosis are apparent. indicating a de-
teriorating myocardium, which is consistent with the human
disease (Nonneman et al. 2012). Regardless of age, these pigs
are susceptible to a stress-mediated sudden death. Early experi-
ments implicated the ryanodine receptor because inhalation of
isoflurane also caused this sudden death (Nonneman et al.
2012), although it is unclear if the death was due to the
isoflurane, per se, or the stress of forced breathing of isoflurane.
Regardless, immediately prior to death during isoflurane inhala-
tion, electrocardiogram (EKG) abnormalities were reported
(Nonneman et al. 2012). Similarly, we found EKG abnormalities
immediately prior to death resulting from acute stress (Figure 1).
It is unclear if the ryanodine receptor is affected by dystrophin in-
sufficiency in this model; however, recent evidence (Bellinger
et al. 2009; Fauconnier et al. 2010) and a similar susceptibility to
sudden death in BMDpatients (Nigro et al. 2002) leads to the spec-
ulation that there may be post-translational ryanodine receptor
modification due to dystrophin insufficiency. Importantly,
hyperthermia was not present during stress-mediated death
(unpublished observations).
Current Approaches
While histological experiments provide compelling evidence that
dystrophin insufficiency leads to disease-related injury in dystro-
phin-insufficient pigs, we are currently working to determine the
extent towhich it leads to impairedmuscle function. This will pro-
vide anobjective outcomemeasure so that disease progressioncan
be clearly tracked and establish a basis on which to evaluate inter-
ventions at the preclinical stage. Further, because it is clear in other
species that dystrophin insufficiency causes lesions in skeletal
muscle and leads to impaired muscle function, establishing this
in the porcine model is critical. Currently, we are using changes
in gait to objectively measure locomotor function. To accomplish
this, pigs are observed as they walk on an ∼15-meter linear track
that contains an ∼5-meter mat with embedded force transducers
(Xeno, ProtoKinetics, Havertown, PA; Figure 2).While this is an on-
going study, our preliminary data indicate that, at threemonths of
age, stride length is decreased (Figure 3) in affectedpigs, andaffect-
ed pigs do not roll through a step (strike to toe off) in the same
fashion as healthy littermates (Selsby, Ross, Nonneman, Kaiser,
unpublished observations). Such changes would be indicative of
disease-related modifications to gait and locomotion much like
those observed in human patients.
Future Directions
To more fully characterize the model, we intend to measure
respiratory function in these pigs because respiratory failure is
a serious clinical concern for these patients. That these pigs
have such a powerful and repeatable stress-induced death cre-
ates some hurdles that we are working to overcome. In an early
attempt to measure respiratory function, we used respiratory
inductive plethysmography in which bands are placed around
the chest and abdomen of the pig. While we were successful in
recording a signal, we were not able to calibrate the system due
to fears that this process would trigger stress sufficient to kill
the animal. We also considered surgical techniques; however,
that precludes the possibility of longitudinal studies. We are cur-
rently exploring the possibility of using whole-body unrestrained
plethysmography and have successfully performed this tech-
nique in mice (Selsby et al. 2014).
Of equal importance are changes in cardiac function, and the
possibility of using theworking heart or Langendorff approaches
to measure cardiac function is foreseeable. We may also pursue
in vivo imaging using magnetic resonance imaging (MRI) and
have recently performed this measure in mice (Ballman et al.
2015; Beyers et al. 2015).
Aside from disease characterization, understanding the mo-
lecular mechanism leading to dystrophin insufficiency is impor-
tant because it will help us to better understand the disease in
thismodel butmay also help us better understand similar causes
in human patients. The reduction in dystrophin abundance is
greater than was anticipated given the identified mutation. Full
sequencing of the dystrophin gene did not reveal additional mu-
tations (Nonneman et al. 2012). Themutation did not cause anew
microRNA binding site, although the molecular properties of ar-
ginine and tryptophan differ. It is reasonable to suggest that this
amino acid substitution changed the tertiary structure, making
proteolytic attackmore likely. Indeed, in silico digests suggest in-
creased susceptibility to calpain (Hollinger et al. 2014). Even this,
however, seems inadequate to explain the 70%–90% reduction in
dystrophin protein abundance, suggesting that some other
mechanism(s) are contributing to decreased dystrophin abun-
dance. These may include decreased stability of the transcript,
increased transcript degradation, or decreased protein stability.
Summary
A variety of animal models have contributed to our under-
standing of dystrophinopathies and to therapy development.
Deficiencies in these models necessitate the development of
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Figure 1. Dystrophic pigs have EKG abnormalities after acute stress. Fifteen minutes after a routine injection, a pig with dystrophin insufficiency collapsed and exhibited
rapid, shallow breathing. EKG pads were applied within a fewminutes to record electrical activity in the heart. Ultimately, the rhythm degraded to ventricular fibrillation
and asystole. The entire duration from the onset of breathing abnormalities to death was less 15 min. Similar recordings, along with an example from a healthy animal
have been previously reported (Nonneman et al. 2012). These panels (in order) were taken over the final 8 min.
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novel, large-animal models as preclinical tools. The pig repre-
sents a human-sized animal that shares many anatomical and
physiological features with humans, including the cardiovascu-
lar system,which is of importance in the study of dystrophinopa-
thies. Several pigmodels are being developed by different groups,
and we have recently described work characterizing a porcine
model with a dystrophin insufficiency and associated muscle in-
jury. We are in the process of characterizing disease progression
and are developing techniques to objectivelymeasure physiolog-
ical outcomes.We are also pursuing themeasurement of respira-
tory and cardiac function. In total, porcine dystrophinopathy
models hold tremendous promise as preclinical models in the
drug and therapy development pipeline for the treatment of
boys afflicted with dystrophinopathies.
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